Tag Archives: drug development

Back to Basics: New Drug for Dyskinesias in Clinical Trials

Do you or a loved one experience dyskinesias as part of Parkinson’s disease (PD)? The Parkinson’s Disease Foundation (PDF) has exciting news that may affect those of you who experience levodopa-induced dyskinesias (LIDs), the twisting and writhing movements that occur when people take levodopa. A few months ago, the Food and Drug Administration (FDA) granted orphan drug status to an experimental PD medication called eltoprazine, which is designed to ease LIDs. This status acknowledges that the drug fills an important unmet need (if approved, it would be the first drug available to treat LIDs) and may allow the drug to become available… read more Read More

Et Tu Nilotinib?: Understanding Headlines about an Anti-Cancer Drug for PD

The Society for Neuroscience annual meeting, which took place last week in Chicago, IL, is a place where the latest preliminary data in neuroscience is presented. True to form, there was an interesting abstract presented by Fernando Pagan, M.D. and colleagues from Georgetown University Hospital which suggested a potential treatment for those with Parkinson’s disease (PD). At the heart of the presentation, Dr. Pagan and colleagues reported that in a small trial, an anti-cancer drug called nilotinib was able to reverse both the movement symptoms and cognitive decline of people with PD involved in the study.

Two New Drugs for PD: A Caregiver & Advocate Speaks Out

Last month, it was announced that two new drugs were approved by the US Food and Drug Administration, for treatment of Parkinson’s disease (PD). Both drugs, Rytary™ and Duopa™, are updates to carbidopa/levodopa. They offer, respectively, a newer formulation and delivery method to reduce off-times for those with PD. In this Q&A, PDF speaks with Myra Hirschhorn, one of our trained Research Advocates, to understand the community reaction to the approvals. As part of the Parkinson’s Advocates in Research program, Myra has been trained in the drug development process, and educates her community about research.